These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15974981)

  • 1. Insights into peptide-based vaccine design for cancer immunotherapy.
    Lazoura E; Apostolopoulos V
    Curr Med Chem; 2005; 12(13):1481-94. PubMed ID: 15974981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Peptide-based vaccine design for cancer immunotherapeutic applications.
    Lazoura E; Apostolopoulos V
    Curr Med Chem; 2005; 12(6):629-39. PubMed ID: 15790302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pMHC Structural Comparisons as a Pivotal Element to Detect and Validate T-Cell Targets for Vaccine Development and Immunotherapy-A New Methodological Proposal.
    Vianna P; Mendes MFA; Bragatte MA; Ferreira PS; Salzano FM; Bonamino MH; Vieira GF
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
    Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
    Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.
    Tsoras AN; Champion JA
    Bioconjug Chem; 2018 Mar; 29(3):776-785. PubMed ID: 29436221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic peptides as cancer vaccines.
    Sundaram R; Dakappagari NK; Kaumaya PT
    Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-based therapeutic cancer vaccine: Current trends in clinical application.
    Liu W; Tang H; Li L; Wang X; Yu Z; Li J
    Cell Prolif; 2021 May; 54(5):e13025. PubMed ID: 33754407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing vaccine potency using TCRmimic antibodies.
    Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
    Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.
    McMahan RH; McWilliams JA; Jordan KR; Dow SW; Wilson DB; Slansky JE
    J Clin Invest; 2006 Sep; 116(9):2543-51. PubMed ID: 16932807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
    Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
    Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor antigens and tumor vaccines: peptides as immunogens.
    Slingluff CL
    Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.